Where is HYLO located?

HYLO is headquartered in Germany.

Is HYLO a funded company?

HYLO is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does HYLO rank among its competitors?

HYLO ranks 43rd amongst 54 active competitors, of which 17 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Biophytis, which secured $1.58M in Mar, 2026.

Who are the top competitors of HYLO?

HYLO's top competitors include Lineage Cell Therapeutics, Remegen and Stellular Bio. Among them, Biophytis secured the most recent funding round in March, 2026.

HYLO - 2026 Company Profile & Competitors

Company Details

Manufacturer of eye care products for dry and tired eyes. The company offers products for eye lubrication, protection, and intensive therapy. Product lines include eye drops and ointments designed to address various levels of eye discomfort. They provide solutions for daily eye stress, gaming, and chronic conditions.

Website: hylo.de
Social
Email ID: *****@ursapharm.de
Phone Number: +49 **********
Part Of

Key Metrics

Founded Year

1999

Location

Germany

Stage

Unfunded

Ranked

43^rd among 54 active competitors

Similar Companies

Lineage Cell Therapeutics & 53 more

View HYLO's full profile

HYLO has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HYLO include Lineage Cell Therapeutics, Remegen and Stellular Bio. Here is the list of Top 10 competitors of HYLO, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
2nd	Remegen 2008, Yantai (China), Public	Developer of therapies for the treatment of cancer, autoimmune and eye diseases	$100M	Lilly Asia Ventures, CDG Capital & 10 others	61/100
3rd	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Vivo Capital, Qiming & 5 others	59/100
4th	Biophytis 2006, Romainville (France), Public	Developer of drugs for neuromuscular and age-related diseases	$2.6M	Kreos Capital, Seventure Partners & 1 others	56/100
5th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, The House Fund & 9 others	55/100
6th	TearSolutions 2013, Charlottesville (United States), Series B	Topical therapeutics for the treatment of dry eye disease	$43M	Center for Innovative Technology, Pharmstandard ... & 5 others	54/100
7th	Azura Ophthalmics 1997, Tel Aviv (Israel), Series C	Developing therapies for meibomian gland dysfunction	$37.2M	Orbimed, Medical Research Commercialisation Fund ... & 4 others	53/100
8th	Retrotope 2006, Los Altos (United States), Acquired	Developer of therapeutics to treat neurodegenerative and ophthalmological diseases	$69.6M	SDL Ventures, Green Park & Golf Ventures ... & 12 others	53/100
9th	Marinomed 2006, Vienna (Austria), Public	Developer of drugs for immunology, allergy and infectious diseases	-	Invest, aws Mittelstandsfonds & 4 others	53/100
10th	VivaVision Biotech 2016, Pudong (China), Series E	Developer of therapeutic solutions for treating multiple eye diseases	$46M	Sequoia Capital China, Viva BioInnovator & 6 others	52/100
43rd	HYLO 1999, Germany, Unfunded	Manufacturer of eye care products for dry and tired eyes	-	-	24/100